Ascendis Pharma A/S Ordinary Share
ASNDStock
$259.80+53.69%52W
Market Cap$19.18B
P/E—
Div yield—
Beta0.31
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)16.46%
Price vs S&P 500 (4W)15.57%
VGM Score58.46
Market Capitalization$19.18B
Earnings Surprise History
Q1 26-0.88est. 0.24
Analyst Recommendations
Apr 2026
May 2026
Jun 2026
Jul 2026
4.42
4.42
4.42
4.42
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ASNDAscendis Pharma A/S Ordinary Share | F | A | B | $259.80 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Ascendis Pharma is a biopharmaceutical company that develops therapeutics using its proprietary TransCon technology platform, with a pipeline focused on endocrinology and oncology indications including TransCon PTH and TransCon CNP. The company primarily generates revenue from the United States, with operations across Europe and international markets.